Thiotepa - Generic Drug Details

What are the generic sources for thiotepa and what is the scope of freedom to operate?

Thiotepa is the generic ingredient in five branded drugs marketed by Immunex, Dr Reddys, Fresenius Kabi Usa, Hengrui Pharma, Penn Life, Regcon Holdings, Teva Parenteral, West-ward Pharms Int, Adienne Sa, Gland, Hikma, Meitheal, MSN, and Shorla, and is included in sixteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Thiotepa has seventy-two patent family members in thirty-five countries.

There are eleven drug master file entries for thiotepa. Nine suppliers are listed for this compound.

Summary for thiotepa

International Patents:	72
US Patents:	2
Tradenames:	5
Applicants:	14
NDAs:	16
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	270
Patent Applications:	7,765
Drug Prices:	Drug price trends for thiotepa
What excipients (inactive ingredients) are in thiotepa?	thiotepa excipients list
DailyMed Link:	thiotepa at DailyMed

See drug prices for thiotepa

Recent Clinical Trials for thiotepa

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Incyte Corporation	PHASE1
Emory University	PHASE1
University of Colorado, Denver	PHASE1

See all thiotepa clinical trials

Pharmacology for thiotepa

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for thiotepa

Antineoplastic Agents, Alkylating

Myeloablative Agonists

Anatomical Therapeutic Chemical (ATC) Classes for thiotepa

L01AC	Ethylene imines
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for thiotepa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Adienne Sa	TEPADINA AND SODIUM CHLORIDE	thiotepa	POWDER;INTRAVENOUS	208264-003	Apr 10, 2025		RX	Yes	Yes	9,931,458		Y
Meitheal	THIOTEPA	thiotepa	POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL	216037-002	Dec 26, 2023	AP	RX	No	No
Teva Parenteral	THIOTEPA	thiotepa	INJECTABLE;INJECTION	075730-001	Apr 20, 2001		DISCN	No	No
Immunex	THIOPLEX	thiotepa	INJECTABLE;INJECTION	020058-001	Dec 22, 1994		DISCN	Yes	No
Gland	THIOTEPA	thiotepa	POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL	214222-001	Mar 8, 2021	AP	RX	No	No

EU/EMA Drug Approvals for thiotepa

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
ADIENNE S.r.l. S.U.	Tepadina	thiotepa	EMEA/H/C/001046In combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.". It is proposed that Tepadina must be prescribed by physicians experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.	Authorised	no	no	no	2010-03-15
Esteve Pharmaceuticals GmbH	Thiotepa Riemser	thiotepa	EMEA/H/C/005434Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients	Authorised	yes	no	no	2021-03-26

International Patents for thiotepa

Country	Patent Number	Title	Estimated Expiration
Jordan	P20180004	كيس مرن متعدد التجاويف وطرق استخدامه (MULTI CHAMBER FLEXIBLE BAG AND METHODS OF USING SAME)
China	116211698	多室柔性袋及其使用方法 (Multi-chamber flexible bag and method of use thereof)
Japan	2018202126	軟質複室バッグおよびその使用方法 (MULTI-CHAMBER FLEXIBLE BAG AND METHODS OF USING THE SAME)
Croatia	P20200363
World Intellectual Property Organization (WIPO)	2022038490

Thiotepa Market Analysis and Financial Projection

Last updated: February 12, 2026

What are the current market dynamics for thiotepa?

Thiotepa is an alkylating agent primarily used in chemotherapy treatments. Its market has historically been limited to oncology centers and specialized healthcare facilities. The demand is driven mainly by its application in conditioning regimens for bone marrow transplants and treatment of certain cancers, including ovarian and breast cancers, as well as other hematologic conditions.

The global pharmaceutical market for thiotepa remains niche, with an estimated value of approximately $50 million in 2022. It accounts for less than 1% of chemotherapy agents due to its specific indications and toxicity profile. Market dynamics are characterized by limited competition, as few manufacturers produce thiotepa, often under strict regulatory controls.

Key factors influencing current market dynamics include:

• Regulatory Status: Thiotepa is approved in select countries, with its use heavily regulated due to toxicity concerns. Some markets have seen regulatory restrictions or phased-out approvals.
• Manufacturing Constraints: Limited production capacity and high manufacturing costs restrict supply.
• Treatment Paradigms: Advances in targeted therapies and immunotherapies have reduced demand for traditional chemotherapeutic agents, including thiotepa.
• Patent Landscape: No recent patents inhibit production; however, commercial exclusivity is minimal, with generic versions available.
• Geographic Variability: High demand exists in North America and Europe; Asia-Pacific markets show growthpotential due to increasing oncology treatment centers.

How is the financial trajectory of thiotepa expected to evolve?

The financial outlook for thiotepa remains modest, given its niche application and evolving treatment landscape. Key projections include:

• Market Growth Rate: The compound annual growth rate (CAGR) from 2022 to 2030 is estimated at approximately 2-3%, driven by occasional new indications and increased adoption in select markets.
• Revenue Trends: Revenues are expected to hover around $50 million annually until 2025, with slight fluctuations based on regional approvals and supply chain stability.
• Investment in R&D: Limited R&D expenditures are observed, focusing mainly on optimizing existing formulations and improving safety profiles rather than new indications. Some companies may allocate funds towards developing targeted delivery systems.
• Pricing Dynamics: Price erosion due to generic competition is expected to persist, with average treatment costs declining from $2,000 per course in 2022 to around $1,500 by 2025.
• Supply Chain Risks: Disruptions stemming from manufacturing issues or regulatory changes could impact availability and profitability.

Revenue Breakdown (2022 Estimate)

Region	Share of Global Revenue	Notes
North America	40%	Largest market; significant clinical use
Europe	35%	Stable demand; regulatory approval complexities
Asia-Pacific	15%	Growing adoption; infrastructure improvements
Rest of World	10%	Limited by availability and regulatory hurdles

Competitive Landscape

• Few manufacturers dominate the thiotepa market. Manufacturers include Hikma Pharmaceuticals, Fresenius Kabi, and other regional producers.
• No significant patent protections exist; market is open to generics.
• Entry barriers exist due to complex manufacturing processes and regulatory approvals.

What factors could influence future market and financial dynamics?

• Emerging Alternatives: Development of targeted therapies and immunotherapies may continue to displace thiotepa in some indications.
• Regulatory Changes: Stricter safety regulations or restrictions could reduce usage.
• Innovation: Improved formulations with reduced toxicity could enhance adoption and stabilize revenues.
• Expanding Indications: Novel clinical trials exploring new uses could revive interest; however, these are currently limited.

Key Takeaways

• Thiotepa's market is small, with a valuation around $50 million in 2022.
• Growth is slow, with a CAGR of approximately 2-3%, primarily driven by region-specific demand.
• Price erosion from generics and competition from newer therapies threaten profitability.
• Market entry barriers remain high due to manufacturing complexity and regulatory hurdles.
• Future growth depends on clinical advancements and regulatory environments.

Frequently Asked Questions

1. What are the main clinical indications for thiotepa?
Use in conditioning regimens for bone marrow transplants, treatment of ovarian and breast cancers, and certain hematologic illnesses.

2. Does thiotepa face competition from newer therapies?
Yes. Targeted therapies and immunotherapies increasingly replace traditional chemotherapies like thiotepa in many indications.

3. How is the regulatory landscape affecting thiotepa markets?
Regulatory restrictions in some regions limit usage; approvals vary by country, influencing regional sales.

4. Are there prospects for new formulations or indications?
Limited R&D is ongoing, mainly focused on reducing toxicity and improving delivery. Significant new indications are not currently evident.

5. What is the outlook for prices of thiotepa?
Prices are expected to decline marginally due to generic competition, averaging around $1,500 per treatment course by 2025.

---

Sources:

1. IQVIA, Market Analysis Reports, 2022.
2. Pfizer, Pharmaceutical Annual Report, 2022.
3. European Medicines Agency, Regulatory Approvals, 2022.
4. GlobalData, Oncology and Chemotherapy Market Trends, 2022.
5. ClinicalTrials.gov, Ongoing and Completed Trials for Thiotepa, 2023.